GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis

NCT07251556 on ClinicalTrials.gov · last registry update 2025-12-02

Registered but not yet open, with 40 participants planned. Due to report 1 January 2027, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Difference in the proportion of subjects with CIMT between the semaglutide group and control group over a period of 24 weeks. Sponsors move these dates routinely; any movement since this site started watching is listed below.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Chinese University of Hong Kong
Sponsor type: Other
Enrollment: 40
Started: 2025-12-01
Primary completion: 2027-01-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Difference in the proportion of subjects with CIMT between the semaglutide group and control group over a period of 24 weeks.

Conditions studied

Psoriasis Arthritis

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.